304 related articles for article (PubMed ID: 29357325)
21. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
[TBL] [Abstract][Full Text] [Related]
22. Perioperative management of a patient undergoing Clagett window closure stabilized on Suboxone® for chronic pain: a case report.
Huang A; Katznelson R; de Perrot M; Clarke H
Can J Anaesth; 2014 Sep; 61(9):826-31. PubMed ID: 24985936
[TBL] [Abstract][Full Text] [Related]
23. Perioperative Buprenorphine Continuous Maintenance and Administration Simultaneous With Full Opioid Agonist: Patient Priority at the Interface Between Medical Disciplines.
Acampora GA; Nisavic M; Zhang Y
J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31917908
[TBL] [Abstract][Full Text] [Related]
24. Buprenorphine-naloxone therapy in pain management.
Chen KY; Chen L; Mao J
Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
[TBL] [Abstract][Full Text] [Related]
25. Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.
Klaire S; Zivanovic R; Barbic SP; Sandhu R; Mathew N; Azar P
Am J Addict; 2019 Jul; 28(4):262-265. PubMed ID: 30901127
[TBL] [Abstract][Full Text] [Related]
26. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
27. The implementation of buprenorphine/naloxone in college health practice.
DeMaria PA; Patkar AA
J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
[TBL] [Abstract][Full Text] [Related]
28. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
DiPaula BA; Menachery E
J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
[TBL] [Abstract][Full Text] [Related]
29. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
30. A prospective, randomized trial of the effect of buprenorphine continuation versus dose reduction on pain control and post-operative opioid use.
Quaye A; Silvia K; Richard J; Ibrahim Y; Craig WY; Rosen C
Medicine (Baltimore); 2022 Dec; 101(51):e32309. PubMed ID: 36595741
[TBL] [Abstract][Full Text] [Related]
31. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
[TBL] [Abstract][Full Text] [Related]
32. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
Curcio F; Franco T; Topa M; Baldassarre C;
Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
[TBL] [Abstract][Full Text] [Related]
35. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Harrison TK; Kornfeld H; Aggarwal AK; Lembke A
Anesthesiol Clin; 2018 Sep; 36(3):345-359. PubMed ID: 30092933
[TBL] [Abstract][Full Text] [Related]
36. Buprenorphine in the treatment of opiate dependence.
Wesson DR; Smith DE
J Psychoactive Drugs; 2010 Jun; 42(2):161-75. PubMed ID: 20648912
[TBL] [Abstract][Full Text] [Related]
37. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
38. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
39. Failure to identify or effectively manage prescription opioid dependence acted as a gateway to heroin use-buprenorphine/naloxone treatment and recovery in a surgical patient.
Conroy S; Hill D
BMJ Case Rep; 2014 Dec; 2014():. PubMed ID: 25519865
[TBL] [Abstract][Full Text] [Related]
40. Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature.
Taveros MC; Chuang EJ
BMJ Support Palliat Care; 2017 Dec; 7(4):383-389. PubMed ID: 27566722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
